Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | RARG | P13631 | 3/20 | 0.43 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656855 | 0.85 | RARB (0.45) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL5656647 | 0.85 | NOTUM (0.44) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL5654523 | 0.83 | NOTUM (0.42) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL9617566 | 0.81 | GAA (0.47) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL9617620 | 0.80 | PTGS1 (0.41) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL23554960 | 0.77 | PKM (0.55) | — | |
| SCHEMBL11450799 | 0.76 | CA2 (0.45) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL16178941 | 0.73 | AKR1B1 (0.45) | NOTUMRARBRARGRARAPTGS2 | |
| SCHEMBL11449845 | 0.73 | ALDH1A1 (0.46) | — | |
| SCHEMBL720137 | 0.73 | NOTUM (0.50) | NOTUMRARBRARGRARAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1487446-A4 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1487446-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003075858-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | PC, CYP27A1, GPR119 | NOTUM 1917/4885RARB 3268/4885RARG 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.